Hoth Therapeutics Inc (HOTH) Stock Price, Quote & News

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 756 2997

Website: hoththerapeutics.com

Address:

1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States

stonkmamma Dec. 23 at 4:29 PM

$HOTH

0 · Reply

PSM_EmpowerTrading Dec. 23 at 2:25 PM

🌅 Watchlist part 2 ✅ $KAVL low $0.20 support; if above $0.30, has potential to $0.40 / $0.50 ✅ $AIRE mid $0.50 support; if above $0.70, has potential to $0.80 / $1.00 ✅ $CETX $2.30 support; if above $2.60, has potential to $2.80 / $3.20 🚨 The above tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entries are near lower support levels 🎯 Ideal stop loss if price breaks below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $HOTH $KTTA still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D

0 · Reply

PSM_EmpowerTrading Dec. 23 at 6:04 AM

🌅 Watchlist part 2 ✅ $CHR.X 1/50 reverse split → new price ~ $1.50 ✅ $BOXL 1/6 reverse split → new price ~ $3.48 🚨 The above tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entries are near key support levels 🎯 Ideal stop loss if price breaks below current support 🚨 Avoid chasing longs into strength near resistance ⏳⏳ $HOTH, $KTTA still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D

0 · Reply

stonkmamma Dec. 22 at 4:13 PM

$HOTH

0 · Reply

PSM_EmpowerTrading Dec. 22 at 2:11 PM

🌅 Watchlist part 2 ✅ $SIDU mid 1.50 support; if above 2.00, has potential to 2.40 / 2.70. CONGRATS if you accumulated during the swing phase below 0.75. ✅ $DVLT low 1.00 support; if above 1.30, has potential to 1.50 / 1.70. 🚨 The above tickers are not ideal for new swing accumulation at current prices 🚨 ✅ Ideal long entries are near key support levels 🎯 Ideal stop loss: below current support 🚨 Avoid chasing into strength near resistance ⏳⏳ $HOTH, $PRSO still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D

1 · Reply

Love_To_Learn Dec. 16 at 7:43 PM

$HOTH been slowly looping u down n applying subtle pressure for some time

1 · Reply

ZdP2 Dec. 16 at 8:39 AM

$HOTH Time to slowly start buying again here around 1$, then wait for the next pop.

0 · Reply

Johnnyb1973 Dec. 10 at 11:34 PM

$HOTH When we finally get the double blind data from HT-001 this will blow right past 5! Mark my words!! 🤜💎🤛

1 · Reply

MahiMe Dec. 10 at 6:59 PM

$HOTH The average one-year price target for Hoth Therapeutics (NasdaqCM:HOTH) has been revised to $4.59 / share. There are 30 funds or institutions reporting positions in Hoth Therapeutics. This is an increase of 10 owner(s) or 50.00% in the last quarter. Citadel Advisors holds 143K shares representing 0.92% ownership of the company. Geode Capital Management holds 154K shares representing 0.99% ownership of the company Renaissance Technologies holds 244K shares representing 1.57% ownership of the company https://www.nasdaq.com/articles/hoth-therapeutics-hoth-price-target-increased-1250-459

0 · Reply

MrTicker Dec. 4 at 5:50 PM

$HOTH D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target BENZINGA 11:50 AM ET 12/4/2025 D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics(HOTH) with a Buy and maintains $5 price target.

0 · Reply

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 1, 2025, 8:03 AM EST - 24 days ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Nov 20, 2025, 8:13 AM EST - 5 weeks ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Oct 27, 2025, 7:49 AM EDT - 2 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 21, 2025, 8:23 AM EDT - 2 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 8, 2025, 8:02 AM EDT - 2 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 7, 2025, 7:57 AM EDT - 2 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Sep 24, 2025, 8:13 AM EDT - 3 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 16, 2025, 8:14 AM EDT - 3 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 10, 2025, 8:29 AM EDT - 3 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 4, 2025, 8:16 AM EDT - 4 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 2, 2025, 8:16 AM EDT - 4 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Jul 29, 2025, 7:58 AM EDT - 5 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 22, 2025, 8:19 AM EDT - 5 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jun 25, 2025, 8:27 AM EDT - 6 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Jun 24, 2025, 10:36 AM EDT - 6 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 23, 2025, 8:03 AM EDT - 6 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 18, 2025, 1:34 PM EDT - 6 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 8:22 AM EDT - 6 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 12, 2025, 9:17 AM EDT - 7 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 11, 2025, 8:28 AM EDT - 7 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 7 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025, 7:30 AM EDT - 8 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Apr 17, 2025, 8:01 AM EDT - 9 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025, 8:19 AM EDT - 9 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025, 8:02 AM EDT - 9 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 7:58 AM EDT - 9 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Mar 31, 2025, 4:45 PM EDT - 9 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 26, 2025, 8:02 AM EDT - 9 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025, 8:06 AM EDT - 10 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 10, 2025, 8:02 AM EDT - 10 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 5, 2025, 1:40 PM EST - 10 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 4, 2025, 8:16 AM EST - 10 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Feb 10, 2025, 8:22 AM EST - 11 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Jan 24, 2025, 8:29 AM EST - 11 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 21, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 17, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 8, 2025, 1:27 PM EST - 1 year ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 7, 2025, 11:53 AM EST - 1 year ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 8:29 AM EST - 1 year ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Dec 26, 2024, 7:58 AM EST - 1 year ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Nov 20, 2024, 7:38 AM EST - 1 year ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Oct 29, 2024, 12:43 PM EDT - 1 year ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 15, 2024, 6:38 AM EDT - 1 year ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Sep 17, 2024, 7:57 AM EDT - 1 year ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 5, 2024, 10:32 AM EDT - 1 year ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 8:03 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Aug 15, 2024, 8:04 AM EDT - 1 year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

stonkmamma Dec. 23 at 4:29 PM

$HOTH

0 · Reply

PSM_EmpowerTrading Dec. 23 at 2:25 PM

0 · Reply

PSM_EmpowerTrading Dec. 23 at 6:04 AM

0 · Reply

stonkmamma Dec. 22 at 4:13 PM

$HOTH

0 · Reply

PSM_EmpowerTrading Dec. 22 at 2:11 PM

1 · Reply

Love_To_Learn Dec. 16 at 7:43 PM

$HOTH been slowly looping u down n applying subtle pressure for some time

1 · Reply

ZdP2 Dec. 16 at 8:39 AM

$HOTH Time to slowly start buying again here around 1$, then wait for the next pop.

0 · Reply

Johnnyb1973 Dec. 10 at 11:34 PM

$HOTH When we finally get the double blind data from HT-001 this will blow right past 5! Mark my words!! 🤜💎🤛

1 · Reply

MahiMe Dec. 10 at 6:59 PM

0 · Reply

MrTicker Dec. 4 at 5:50 PM

0 · Reply

JarvisFlow Dec. 4 at 5:50 PM

D. Boral Capital updates rating for Hoth Therapeutics ( $HOTH ) to Buy, target set at 5.

0 · Reply

stonkmamma Dec. 4 at 2:37 PM

$HOTH

0 · Reply

merlin8121 Dec. 4 at 12:22 PM

$HOTH Hoth Therapeutics: Updated Pipeline, SEC Insights and Sentiment Overview (Dec 2025) https://www.merlintrader.com/hoth-therapeutics/

0 · Reply

MahiMe Dec. 3 at 7:43 PM

$HOTH Pipeline Highlights 1) HT-001 – Phase 2 CLEER-001 Trial Advancing.Strong safety profile to date with no dose-limiting toxicities observed 2) HT-KIT (Orphan Drug Designation for Mast Cell Diseases) – IND Preparation Underway.FDA Orphan Drug Designation already granted. Hoth expects to finalize its' IND submission in 2026, followed by first-in-human studies. 3) HT-ALZ (Therapeutic for Alzheimer's Disease) – Advancing Through GLP and PK Development.Regulatory-facing package expected to mature in 2026. 4) GDNF-Based Weight-Loss & Metabolic Program (VA Collaboration) – Newly Accelerated Initiative,representing one of the largest and fastest-growing therapeutic markets globally. Upcoming Milestones --- CLEER-001 Phase 2 HT-001 clinical data update --- Completion of toxicology and IND filing for HT-KIT --- GLP, BBB, and PK updates for HT-ALZ ---- VA metabolic program early findings

2 · Reply

MahiMe Dec. 3 at 7:32 PM

$HOTH NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships. https://finance.yahoo.com/news/hoth-therapeutics-issues-comprehensive-pipeline-190000629.html

0 · Reply

Biotechs5454 Dec. 3 at 7:17 PM

$HOTH HT-001 is the only thing that will provide meaningful and sustainable MC growth. Glad they finally provided some sort of update. Pops on any of this other nonsense like crypto, AI, weight loss blah blah should be sold. History shows that is the right play but to each their own. GL.

0 · Reply

Go_Stock_yourself Dec. 3 at 7:10 PM

$HOTH "Hoth Therapeutics provides pipeline update on four drug programs" https://ca.investing.com/news/assorted/hoth-therapeutics-provides-pipeline-update-on-four-drug-programs-432SI-4347084

0 · Reply

Tino321 Dec. 3 at 7:10 PM

$HOTH come on HOTH

0 · Reply

MahiMe Dec. 1 at 8:59 PM

$HOTH Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 https://sg.finance.yahoo.com/news/hoth-therapeutics-present-noble-capital-130300498.html

0 · Reply

RaphaelRapoport Dec. 1 at 12:19 PM

$HOTH If we just slowly accumulate like this and hold gains - we can silently get back to fair market value. This stock is massively undervalued. Let's go HOTH.

0 · Reply

Tino321 Dec. 1 at 7:32 AM

$HOTH let’s get to 2$ this week🫣

0 · Reply

King_Iceman_the_Great Nov. 28 at 7:42 PM

$HOTH Way too low in price, zero debt and a LOT of cash on the balance sheet. It's time to buy stock in Hoth Therapeutics for the future.

0 · Reply

Market Cap	16.60M
Revenue (ttm)	0.00
Net Income (ttm)	-8.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	175,800
Avg Vol	340,184
Day's Range	N/A - N/A
Shares Out	15.51M
Stochastic %K	14%
Beta	0.64
Analysts	Strong Sell
Price Target	$4.50